More effective MS treatments increase productivity

Disease-modifying therapies (DMTs) for multiple sclerosis (MS) that are most effective are more likely to increase work attendance, work carried out and productivity than less effective alternatives, say Australian investigators (J Neurol Neurosurg Psychiatry: 19 June 2018. doi: 10.1136/jnnp-2018-318228).
They reviewed data from the Australian MS …

More details...

Cannabis effective in childhood epilepsy, review finds

After the recent controversy surrounding the Home Office’s confiscation and subsequent return of medicinal cannabis used to treat a child’s epilepsy prompted a review of legislation by the Home Office (www.gov.uk/government/news/home-office-launches-review-into-medical-use-of-cannabis), specialists in the UK and Australia have published a timely systematic review of its …

More details...

Schizophrenia mortality still high

Life expectancy is increasing in people with schizophrenia at about the same rate as in the general population but it remains well below what others can expect, a study from Finland suggests (Acta Psychiatrica Scand 2018; doi.org/10.1111/acps.12913).
Age at death and standardised mortality ratio (SMR) were …

More details...

NHS England helps service users raise concerns

NHS England has published a guide for patients, families and carers of people with a learning disability and autistic people to help them provide feedback, raise concerns and make complaints about education, health and social care services.
The 8-page booklet Ask Listen Do. Making conversations count …

More details...

Treatment for female hyposexual desire disorder edges closer

Palatin Technologies has applied to the US Food and Drug Administration for marketing approval for melanocortin-receptor-4 agonist bremelanotide for the treatment of female hyposexual desire disorder.
Palatin says the two 24-week Phase III RECONNECT trials involving over 1200 women – so far unpublished – have …

More details...

Europe agrees measures to stop valproate use during pregnancy

European states are set to ban valproate for treating migraine or bipolar disorder and to limit its use to treat epilepsy as a last resort. Women or girls of childbearing age for whom it is prescribed will be required to join a pregnancy prevention programme …

More details...

Developments in treatments for MS

Roche’s monoclonal antibody ocrelizumab (Ocrevus) has become the first medicine licensed for the treatment of primary progressive multiple sclerosis (PPMS) following EU approval in January. It is also licensed for relapsing MS (RMS), an indication that now has a wide range of treatment options.
Ocrelizumab selectively …

More details...

Adjunctive treatment fails to help Alzheimer’s disease

The 5-hydroxytryptamine-6 receptor antagonist idalopirdine did not improve cognition in people with mild to moderate Alzheimer’s disease when added to treatment with a cholinesterase inhibitor, a series of Phase III trials has shown (JAMA 2018;319:130-142). The three 6-month trials involved a total of 2,525 patients …

More details...

Government consults on children’s mental health

The Government published proposals to improve mental health support for children and young people at the beginning of December 2017. Its Green Paper, Transforming children and young people’s mental health provision, ‘focuses on earlier intervention and prevention particularly in or linked to schools and colleges’ …

More details...

Consensus statement calls for better treatment for personality disorder

The mental health system ‘isn’t working as it needs to work’ for people diagnosed with personality disorder, according to a consensus statement from organisations such as Mind, the British Psychological Society, the Centre for Mental Health and the Royal College of General Practitioners.
Shining lights in …

More details...

Web design and marketing agency Leamington Spa